AlzProtect is a biopharmaceutical company discovering and developing drug candidates, for the treatment of neurodegenerative diseases including Alzheimer’s disease (AD) and orphan tauopathies such as Progressive Supranuclear Palsy (PSP).

Our lead compound, AZP2006, is currently in clinical phase 1

Multiple ascending dose study in healthy volunteers is ongoing. These studies show that AZP2006 was well tolerated.

AZP2006

Targeted therapeutical areas

News